In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or the participants are unable to tolerate the study drugs. 88 These preclinical studies supply paradigms for potential clinical trials in AML, and https://davidb322mxi4.blog-eye.com/profile